|
Press Releases |
|
 |
|
Friday, May 13, 2022 |
|
祝贺!国际顶级医学期刊《自然-医学》同时发表两篇关于华领医药全球首创糖尿病新药多格列艾汀的III期研究结果的同行评议论文 |
华领医药(“公司”,香港联交所主板股份代号:2552.HK)今日宣布,国际顶级医学刊物《自然-医学》(Nature Medicine)杂志同时在线发表了两篇公司全球首创糖尿病新药葡萄糖激酶激活剂(GKA)多格列艾汀(dorzagliatin)的III期注册临床研究结果的同行评议论文。 more info >> |
|
祝賀!國際頂級醫學期刊《自然-醫學》同時發表兩篇關於華領醫藥全球首創糖尿病新藥多格列艾汀的III期研究結果的同行評議論文 |
華領醫藥(“公司”,香港聯交所主機板股份代號:2552.HK)今日宣佈,國際頂級醫學刊物《自然-醫學》(Nature Medicine)雜誌同時線上發表了兩篇公司全球首創糖尿病新藥葡萄糖激酶啟動劑(GKA)多格列艾汀(dorzagliatin)的III期註冊臨床研究結果的同行評議論文。 more info >> |
|
Hua Medicine Published Two Peer-Reviewed Papers in Nature Medicine, an International Top Medical Journal, on the Results of the Phase III Research of Dorzagliatin, a First-In-Class Investigational Diabetes Drug of Hua Medicine |
Hua Medicine (the "Company", stock code on the main board of the Hong Kong Stock Exchange: 2552.HK) today announces that, two peer-reviewed papers on the Phase III clinical trial results of dorzagliatin more info >> |
|
Thursday, March 17, 2022 |
|
华领医药公布2021年全年业绩 |
华领医药(「公司」,香港联交所股份代号:2552),今天宣布公司及其附属公司截至2021年12月31日止,经审核的全年业绩(「报告期」)。 more info >> |
|
華領醫藥公佈2021年全年業績 |
華領醫藥(「公司」,香港聯交所股份代號:2552),今天宣佈公司及其附屬公司截至2021年12月31日止,經審核的全年業績(「報告期」)。 more info >> |
|
Hua Medicine Announces 2021 Annual Results |
Hua Medicine (the "Company", Stock Code: 2552.HK) today announces the audited annual results of the Company and its subsidiaries for the year ended December 31, 2021 (the "Reporting Period"). The Reporting Period witnessed significant milestones in the commercialization process of dorzagliatin. more info >> |
|
Sunday, September 26, 2021 |
|
Researchers Present Key Research Results on Diabetes Remission of Dorzagliatin |
Hua Medicine (2552.HK) announced that at the 6th China BioMed Innovation & Investment Conference (CBIIC), Professor Jianhua MA, Director, Department of Endocrinology, Nanjing First Hospital, Standing Member of the Chinese Diabetes Society, as one of the principal researchers presented the results from a clinical study called DREAM, which showed that dorzagliatin, a glucokinase activator and a first-in-class investigational drug of Hua Medicine, may make progress in diabetes remission. more info >> |
|
研究者公佈有關多格列艾汀糖尿病緩解的重要研究 |
more info >> |
|
研究者公布有关多格列艾汀糖尿病缓解的重要研究 |
华领医药(「公司」,香港联交所股份代号:2552.HK)今天宣布,在苏州举办的第六届中国医药创新与投资大会(The China BioMed Innovation and Investment Conference,以下简称CBIIC)上,中华医学会糖尿病学分会常委、南京市第一医院内分泌科主任马建华教授作为主要研究者之一,公布了一项名为DREAM的临床研究结果,研究显示华领医药全球首创新药葡萄糖激酶激活剂多格列艾汀(dorzagliatin) 有望在糖尿病缓解方面取得进展。 more info >> |
|
Wednesday, September 15, 2021 |
|
华领医药与国药控股签署供应链战略合作协议 加速商业化布局 |
2021年9月13日,华领医药技术(上海)有限公司(「华领医药」,香港联交所股份代号:2552)与国药控股股份有限公司(「国药控股」,香港联交所股份代号:1099)签署供应链战略合作协议,将在物流仓储、供应链管理和渠道信息化等方面展开深入合作 more info >> |
|
|
|
|
|
|
|
|
Latest Press Releases |
|
荧德控股年度收益增加32.8%创新高
May 17, 2022 23:02 HKT/SGT
|
|
|
熒德控股年度收益增加32.8%創新高
May 17, 2022 23:01 HKT/SGT
|
|
|
Vistar Holdings Hits Record High Annual Revenue Up by 32.8% Y-o-Y
May 17, 2022 23:00 HKT/SGT
|
|
|
莲鑫集团下属莲鑫基金与安谋科技中方股东就收购安谋科技51%股权签署意向书
May 17, 2022 21:30 HKT/SGT
|
|
|
神鋼集團:關於日本國內首次低碳高爐鋼材''Kobenable Steel''的商品化
May 17, 2022 16:00 HKT/SGT
|
|
|
神钢集团:关于日本国内首次低碳高炉钢材''Kobenable Steel''的商品化
May 17, 2022 16:00 HKT/SGT
|
|
|
Kobe Steel to launch "Kobenable Steel", Japan's first low CO2 blast furnace steel
May 17, 2022 16:00 HKT/SGT
|
|
|
Deputy Directors from Kenyan Ministry of ICT and ICT Authority along with INTERPOL's Director of Cybercrime to speak at CyFrica 2022
May 17, 2022 15:09 HKT/SGT
|
|
|
积极回馈投资者产品屡获殊荣 金嗓子用实力铸就坚强品牌内核
May 17, 2022 14:28 HKT/SGT
|
|
|
積極回饋投資者產品屢獲殊榮 金嗓子用實力鑄就堅強品牌內核
May 17, 2022 14:27 HKT/SGT
|
|
|
Yew Lee Pacific Group Berhad Launches Prospectus for ACE Market IPO
May 17, 2022 12:30 HKT/SGT
|
|
|
三菱重工、バーレーンの大手国営アルミニウム精錬会社・アルバ社とEPC契約を締結
May 17, 2022 12:20: JST
|
|
|
昭和電工、不飽和ポリエステル樹脂およびビニルエステル樹脂の販売価格改定を発表
May 17, 2022 11:30: JST
|
|
|
Alba Signs Agreement with Mitsubishi Power & SEPCOIII as EPC Contractor for Block 4 in Power Station 5
May 17, 2022 12:26 JST
|
|
|
富士通と理化学研究所、スーパーコンピュータ「富岳」とシミュレーション融合型AIを活用した次世代IT創薬技術の共同研究を開始
May 17, 2022 11:20: JST
|
|
|
|
More News >> |
|
|
|
|
|